Sagility has announced its financial results for Q3 FY26, showcasing strong growth. Revenue reached ₹19,712 million, a 35.7% year-over-year increase. Adjusted EBITDA stood at ₹5,125 million, with a margin of 26.0%. The company also reported an adjusted PAT of ₹3,229 million, demonstrating its continued financial strength and operational efficiency.
Key Financial Highlights for Q3 FY26
Sagility’s Q3 FY26 results demonstrate significant financial achievements:
- Revenue: ₹19,712 million, up 35.7% year-over-year (29.1% at constant currency).
- Adjusted EBITDA: ₹5,125 million, representing a margin of 26.0%.
- Adjusted PAT: ₹3,229 million, with a margin of 16.4%.
- Organic revenue growth reached 19.9% (13.9% at constant currency).
The company also reported winning new business and expansions valued at $30.5 million in potential steady-state ACV.
9M FY26 Performance Overview
The company’s performance over the first nine months of FY26 also showed strong results:
- Revenue: ₹51,686 million, a 29.2% year-over-year increase (24.2% at constant currency).
- Adjusted EBITDA: ₹13,164 million, with a margin of 25.5%.
- Adjusted PAT: ₹8,236 million, reflecting a margin of 15.9%.
Operational Metrics
Sagility reported the following operational metrics:
- Headcount: 48,522 employees.
- Clinicians & Technology Heads: Over 4,100 professionals.
Strategic Recognitions
Sagility was recognized as an:
- Innovator in RCM Business Process Transformation by Avasant’s RadarView™ 2025.
- One of India’s Best Workplaces™ in Pharmaceuticals, Healthcare, and Biotech 2025.
- Received the Ecovadis Committed Badge for strong sustainability performance.
Cash Flow Details
Key cash flow metrics for the nine-month period include:
- Net cash flow from operating activities: ₹6,703 million.
- Free cash flow: ₹5,359 million.
Source: BSE
